MediciNova

MNOV · NASDAQ

$1.36−$0.04 (−2.86%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.40

MNOV analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy4
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $8.41 (+518.7% upside)

Low: $6.06
Now: $1.36
High: $11.55

Upgrades and downgrades

The latest rating actions, newest first

MNOV analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Roth Capital	Sep 17, 2026	Initiates	Buy	$6.00	44%
D. Boral Capital	May 4, 2026	Maintains	Buy	$9.00	29%
Maxim Group	Mar 23, 2026	Initiates	Buy	$6.00	27%
HC Wainwright & Co.	Mar 16, 2026	Initiates	Buy	$10.00	29%
D. Boral Capital	Jan 30, 2026	Maintains	Buy	$9.00	29%
D. Boral Capital	Dec 18, 2025	Maintains	Buy	$9.00	29%
D. Boral Capital	Dec 8, 2025	Maintains	Buy	$9.00	29%
D. Boral Capital	Nov 4, 2025	Maintains	Buy	$9.00	29%
D. Boral Capital	Oct 31, 2025	Maintains	Buy	$9.00	29%

The case for and against

Updated Jul 21, 2026

Bull case

MediciNova is a biopharmaceutical company with a promising pipeline of novel therapeutics for serious diseases, including neurological disorders, fibrotic conditions, and metabolic disorders. With its lead program MN-166 showing promise in multiple indications, ongoing enrollment in clinical trials, and potential regulatory submissions, the company has a strong foundation for growth. The recent publication in Cancer Research validating the mechanism of action for MN-166 in brain metastases adds a new indication to its portfolio, increasing its potential for success. Despite the inherent risks in drug development, MediciNova's strategy of combining controlled clinical evidence with expanded access data enhances its chances of success and mitigates regulatory risk.

Bear case

MediciNova is in the early stages of developing treatments for various neurological and metabolic diseases. However, the company's financials and key data metrics are not strong indicators of success, with inconsistent profitability and low levels of cash reserves. Additionally, their focus on the U.S. market limits their potential reach and revenue opportunities.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.